Bio-Path Holdings announced enrollment is now resuming into its Phase I clinical trial evaluating its lead compound, Liposomal Grb-2, in blood cancers. Sufficient drug quantities are now in place to complete Cohort 6 of the trial. To date, Bio-Path has successfully completed five cohorts of the Phase I clinical trial and has treated two patients in the sixth cohort. The trial requires three evaluable patients per cohort. The company intends to evaluate patient results at the end of Cohort 6 to determine if the optimal biological dose has been reached, which would bring a close to the Phase I clinical trial.